Ajimizu H - Search Results

1

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.

Hashimoto K, Ozasa H, Yoshizawa A, Yoshida H, Ogimoto T, Hosoya K, Yamazoe M, Ajimizu H, Funazo T, Yoshida H, Sakamori Y, Hirai T. Hashimoto K, et al. Among authors: ajimizu h. Oncol Lett. 2022 Sep 22;24(5):402. doi: 10.3892/ol.2022.13522. eCollection 2022 Nov. Oncol Lett. 2022. PMID: 36276492 Free PMC article.

2

Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma.

Tsuji T, Kim YH, Ozasa H, Sakamori Y, Nagai H, Ajimizu H, Yagi Y, Furukawa A, Haga H, Mishima M. Tsuji T, et al. Among authors: ajimizu h. Respir Med Case Rep. 2015 May 15;15:48-50. doi: 10.1016/j.rmcr.2015.05.003. eCollection 2015. Respir Med Case Rep. 2015. PMID: 26236601 Free PMC article.

3

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.

Shima H, Ozasa H, Tsuji T, Ajimizu H, Nomizo T, Yagi Y, Sakamori Y, Nagai H, Minamiguchi S, Kim YH, Mishima M. Shima H, et al. Among authors: ajimizu h. Mol Clin Oncol. 2016 May;4(5):715-718. doi: 10.3892/mco.2016.803. Epub 2016 Mar 7. Mol Clin Oncol. 2016. PMID: 27123268 Free PMC article.

4

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

Tsuji T, Sakamori Y, Ozasa H, Yagi Y, Ajimizu H, Yasuda Y, Funazo T, Nomizo T, Yoshida H, Nagai H, Maeno K, Oguri T, Hirai T, Kim YH. Tsuji T, et al. Among authors: ajimizu h. Oncotarget. 2017 May 16;8(42):71805-71816. doi: 10.18632/oncotarget.17895. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069748 Free PMC article.

5

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

Tsuji T, Ozasa H, Aoki W, Aburaya S, Funazo T, Furugaki K, Yoshimura Y, Ajimizu H, Okutani R, Yasuda Y, Nomizo T, Uemasu K, Hasegawa K, Yoshida H, Yagi Y, Nagai H, Sakamori Y, Ueda M, Hirai T, Kim YH. Tsuji T, et al. Among authors: ajimizu h. Mol Cancer Res. 2019 Jan;17(1):212-224. doi: 10.1158/1541-7786.MCR-18-0325. Epub 2018 Aug 31. Mol Cancer Res. 2019. PMID: 30171175

6

Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.

Yoshida H, Kim YH, Ozasa H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Yamamoto T, Ajimizu H, Hirai T. Yoshida H, et al. Among authors: ajimizu h. In Vivo. 2018 Nov-Dec;32(6):1587-1590. doi: 10.21873/invivo.11418. In Vivo. 2018. PMID: 30348720 Free PMC article.

7

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.

Tsuji T, Ozasa H, Aoki W, Aburaya S, Yamamoto Funazo T, Furugaki K, Yoshimura Y, Yamazoe M, Ajimizu H, Yasuda Y, Nomizo T, Yoshida H, Sakamori Y, Wake H, Ueda M, Kim YH, Hirai T. Tsuji T, et al. Among authors: ajimizu h. Nat Commun. 2020 Jan 3;11(1):74. doi: 10.1038/s41467-019-13771-5. Nat Commun. 2020. PMID: 31900393 Free PMC article.

8

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X_L expression.

Yasuda Y, Ozasa H, Kim YH, Yamazoe M, Ajimizu H, Yamamoto Funazo T, Nomizo T, Tsuji T, Yoshida H, Sakamori Y, Nakajima N, Menju T, Yoshizawa A, Date H, Hirai T. Yasuda Y, et al. Among authors: ajimizu h. Cell Death Dis. 2020 Mar 9;11(3):177. doi: 10.1038/s41419-020-2379-2. Cell Death Dis. 2020. PMID: 32152266 Free PMC article.

9

Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.

Funazo T, Tsuji T, Ozasa H, Furugaki K, Yoshimura Y, Oguri T, Ajimizu H, Yasuda Y, Nomizo T, Sakamori Y, Yoshida H, Kim YH, Hirai T. Funazo T, et al. Among authors: ajimizu h. Mol Cancer Ther. 2020 Jun;19(6):1320-1327. doi: 10.1158/1535-7163.MCT-19-0649. Epub 2020 Mar 26. Mol Cancer Ther. 2020. PMID: 32217741

10

PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.

Yoshida H, Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Ajimizu H, Yamazoe M, Kuninaga K, Ogimoto T, Hosoya K, Itotani R, Sakamori Y, Kim YH, Hirai T. Yoshida H, et al. Among authors: ajimizu h. Eur J Cancer. 2021 Feb;144:317-325. doi: 10.1016/j.ejca.2020.11.035. Epub 2020 Dec 30. Eur J Cancer. 2021. PMID: 33385948

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page